標(biāo)題: Titlebook: Genomic Medicine; A Practical Guide Laura J. Tafe,Maria E. Arcila Book 2020 Springer Nature Switzerland AG 2020 hematopoietic disorders.Pha [打印本頁(yè)] 作者: Lipase 時(shí)間: 2025-3-21 18:32
書目名稱Genomic Medicine影響因子(影響力)
作者: Flustered 時(shí)間: 2025-3-21 20:38
Next-Generation SequencingNGS wet lab and dry lab processing. The library preparation process prepares the substrates to be sequenced through nucleic acid isolation, fragmentation, isolation, end repair, adapter ligation, size selection, and target enrichment. Several types of sequencers exist, with sequencing by ligation, s作者: 無(wú)瑕疵 時(shí)間: 2025-3-22 00:28
Cell-Free DNA Testingome a ubiquitous companion modality for diagnosis, prognosis, treatment selection, and recurrence detection for myriad medical conditions. In this chapter, we aim to provide an overview of current and potential cfDNA applications, specimen collection and assay design considerations, and technology u作者: right-atrium 時(shí)間: 2025-3-22 07:33 作者: 思想流動(dòng) 時(shí)間: 2025-3-22 10:36
Interpreting Genomic Reports cover several or most genes (gene panels), the exome, or the whole genome and have the potential to identify multiple variants. To avoid errors in interpretation, clinicians need to familiarize themselves with the report format and understand each section of the report. In this chapter, we provide 作者: Foment 時(shí)間: 2025-3-22 13:28 作者: Foment 時(shí)間: 2025-3-22 17:59
GI Including GISTmicrosatellite instability, KRAS and BRAF mutations and . gene amplifications. Other molecular biomarkers are emerging as clinically important as new resistance mechanisms are identified and/or as new targeted therapies are developed. In gastrointestinal stromal tumors (GISTs), molecular tests are c作者: 奴才 時(shí)間: 2025-3-23 00:43 作者: cogent 時(shí)間: 2025-3-23 02:56 作者: 我不怕?tīng)奚?nbsp; 時(shí)間: 2025-3-23 08:34 作者: misshapen 時(shí)間: 2025-3-23 11:22
Sarcomas be seen in sarcomas. The first comprises of tumors with translocations or alternatively specific activating or inactivating mutations within oncogenes or tumor suppressor genes, respectively. Often these tumors occur in a setting of simple karyotype. The second major group is associated with multip作者: Foregery 時(shí)間: 2025-3-23 14:37
Salivary Gland Carcinomasmong those that are present in the majority of cases and are the hallmark of disease are . and . fusions in mucoepidermoid carcinoma and . rearrangements in adenoid cystic carcinoma. Similarly, . rearrangement is specific for myoepithelial carcinoma but is present only in the minority of cases. Mole作者: LIKEN 時(shí)間: 2025-3-23 18:45
Sinonasal Carcinomasentiated carcinoma (SNUC) are rare and biologically aggressive, and, although often histologically remarkably similar, these three entities are genetically very distinct. An accurate molecular diagnosis portends a diagnostic value and can identify patients eligible for clinical trials with targeted 作者: Cleave 時(shí)間: 2025-3-24 02:03
Acute Myeloid Neoplasmseous subgroup of myeloid neoplasms with an aggressive clinical course, and the majority of these cases are defined by their underlying genetics. Cytogenetic evaluation retains a primary role in the evaluation and subclassification of these entities, but incorporation of molecular sequencing data has作者: keloid 時(shí)間: 2025-3-24 04:47 作者: 圓柱 時(shí)間: 2025-3-24 09:22 作者: 高腳酒杯 時(shí)間: 2025-3-24 12:21 作者: 印第安人 時(shí)間: 2025-3-24 16:58
Clinical Presentation and Diagnosis,on the file structure, conceptualizing the algorithmic processes, and regulatory considerations. We also discuss some of the tools that are becoming more commonly implemented and are likely to become standard components of many laboratories.作者: meretricious 時(shí)間: 2025-3-24 21:43 作者: Interdict 時(shí)間: 2025-3-25 02:42
Infantile and Neonatal Marfan Syndrome, diagnosis and in the monitoring phase to assess disease progression and for risk stratification across the disease spectra. In this chapter, we highlight the most common somatic genetic abnormalities identified in this group of diseases.作者: HARP 時(shí)間: 2025-3-25 05:58 作者: Leaven 時(shí)間: 2025-3-25 09:16
Role of Bioinformatics in Molecular Medicineon the file structure, conceptualizing the algorithmic processes, and regulatory considerations. We also discuss some of the tools that are becoming more commonly implemented and are likely to become standard components of many laboratories.作者: Antioxidant 時(shí)間: 2025-3-25 14:26 作者: Jubilation 時(shí)間: 2025-3-25 18:31 作者: FOIL 時(shí)間: 2025-3-25 23:55 作者: Conflict 時(shí)間: 2025-3-26 03:41
Surgical Treatment of Primary Aldosteronism well. This chapter summarizes the most clinically significant somatic genetic alterations in breast cancer and how this information can be used to facilitate diagnosis, provide potential treatment options, and identify mechanisms of resistance.作者: 滲入 時(shí)間: 2025-3-26 06:50
Olufemi R. Ayeni,Jón Karlsson,Marc R. Safranance of urothelial carcinoma is forwarded. The potential practical implications of a recently proposed genomic-based taxonomy for bladder cancer is discussed. Practice-based take-home messages are emphasized.作者: CHARM 時(shí)間: 2025-3-26 11:37 作者: BLINK 時(shí)間: 2025-3-26 14:17
Breast well. This chapter summarizes the most clinically significant somatic genetic alterations in breast cancer and how this information can be used to facilitate diagnosis, provide potential treatment options, and identify mechanisms of resistance.作者: 比目魚 時(shí)間: 2025-3-26 19:47 作者: 煞費(fèi)苦心 時(shí)間: 2025-3-27 00:25
dThe field of Molecular Diagnostics is rapidly evolving and molecular characterization of neoplasms is becoming an increasingly important part of the pathologic work up and diagnosis of many tumor types. This work provides a high-yield reference book that compiles critical information related to mol作者: ZEST 時(shí)間: 2025-3-27 05:01 作者: 歡笑 時(shí)間: 2025-3-27 08:09 作者: Anecdote 時(shí)間: 2025-3-27 10:19
https://doi.org/10.1007/978-1-4613-2623-6enetic evaluation retains a primary role in the evaluation and subclassification of these entities, but incorporation of molecular sequencing data has quickly become increasingly important for diagnosis, prognosis, and clinical management.作者: Jocose 時(shí)間: 2025-3-27 17:03
Prognostic Factors in Melanoma,etic events, not a single mutation that is the target of specific therapeutic agents, as is more common in the solid tumors. Therefore, this chapter focuses more on these patterns of genetic lesions rather than focusing solely on targetable ones.作者: FEAT 時(shí)間: 2025-3-27 20:15
Interpreting Genomic Reportsterpretation, clinicians need to familiarize themselves with the report format and understand each section of the report. In this chapter, we provide a description on the molecular pathology report format and a quick guide on how to interpret genomic reports for germline (inherited) mutations and somatic (acquired) mutations.作者: CYT 時(shí)間: 2025-3-27 23:38 作者: NIP 時(shí)間: 2025-3-28 04:07 作者: 文件夾 時(shí)間: 2025-3-28 06:33 作者: 妨礙 時(shí)間: 2025-3-28 12:21
Book 2020athologic work up and diagnosis of many tumor types. This work provides a high-yield reference book that compiles critical information related to molecular biomarkers for various solid tumor and hematologic malignancy subtypes. It is succinct yet comprehensive enough to be suitable for fellows in tr作者: preservative 時(shí)間: 2025-3-28 17:12 作者: 盟軍 時(shí)間: 2025-3-28 20:27 作者: 簡(jiǎn)略 時(shí)間: 2025-3-29 01:13 作者: FRONT 時(shí)間: 2025-3-29 05:28
Pathophysiology: Gut Liver Axis Changes,t for Trk-inhibitors. In contrast, salivary duct carcinoma, a prototype of a high-grade salivary gland cancer, is characterized by a heterogeneous molecular background but a relatively high proportion of potentially targetable mutations. These include frequent ., ., and . alterations and less commonly gene fusions such as ., and ..作者: 到婚嫁年齡 時(shí)間: 2025-3-29 07:48 作者: 配置 時(shí)間: 2025-3-29 14:22
GI Including GISTarly onset of cancer. This chapter discusses established and emerging molecular biomarkers in CRC, upper GI adenocarcinomas, and GISTs. It also summarizes common hereditary GI cancer syndromes and the genetic alterations that underlie them.作者: notion 時(shí)間: 2025-3-29 17:59 作者: CLEFT 時(shí)間: 2025-3-29 21:21
Salivary Gland Carcinomast for Trk-inhibitors. In contrast, salivary duct carcinoma, a prototype of a high-grade salivary gland cancer, is characterized by a heterogeneous molecular background but a relatively high proportion of potentially targetable mutations. These include frequent ., ., and . alterations and less commonly gene fusions such as ., and ..作者: patriarch 時(shí)間: 2025-3-30 02:24 作者: 不安 時(shí)間: 2025-3-30 05:39 作者: 縮減了 時(shí)間: 2025-3-30 10:27
https://doi.org/10.1007/978-3-030-22922-1hematopoietic disorders; Pharmacogenomics; Immunotherapy; drug targets; epigenetics; FISH作者: abduction 時(shí)間: 2025-3-30 14:08 作者: 走調(diào) 時(shí)間: 2025-3-30 19:13
Diagnosis and Fault-Tolerant Controlome a ubiquitous companion modality for diagnosis, prognosis, treatment selection, and recurrence detection for myriad medical conditions. In this chapter, we aim to provide an overview of current and potential cfDNA applications, specimen collection and assay design considerations, and technology used to detect and evaluate cfDNA.作者: 人類學(xué)家 時(shí)間: 2025-3-30 21:08
Cell-Free DNA Testingome a ubiquitous companion modality for diagnosis, prognosis, treatment selection, and recurrence detection for myriad medical conditions. In this chapter, we aim to provide an overview of current and potential cfDNA applications, specimen collection and assay design considerations, and technology used to detect and evaluate cfDNA.作者: 完成 時(shí)間: 2025-3-31 02:09 作者: 耐寒 時(shí)間: 2025-3-31 07:51
Diagnosis of I/O Automata Networksalytic variables that affect these tests and the limitations for each test used to detect these abnormalities. Many limitations of testing start before the tests are even performed. In this chapter, we will review pre-analytical variables affecting the molecular evaluation, the landscape of current 作者: 軍械庫(kù) 時(shí)間: 2025-3-31 12:36 作者: 熟練 時(shí)間: 2025-3-31 16:44
Diagnosis and Fault-Tolerant Controlome a ubiquitous companion modality for diagnosis, prognosis, treatment selection, and recurrence detection for myriad medical conditions. In this chapter, we aim to provide an overview of current and potential cfDNA applications, specimen collection and assay design considerations, and technology u作者: BLOT 時(shí)間: 2025-3-31 20:42 作者: 思想流動(dòng) 時(shí)間: 2025-3-31 22:12 作者: 調(diào)色板 時(shí)間: 2025-4-1 05:11 作者: FAR 時(shí)間: 2025-4-1 08:30 作者: 武器 時(shí)間: 2025-4-1 12:03 作者: arbovirus 時(shí)間: 2025-4-1 18:10
